Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NHS (National Health Service) cervical screening frequency/range "correct":

This article was originally published in Clinica

Executive Summary

Last year's decision by the UK to reduce the cervical screening call-up interval among women aged 25-49, from five years to three, will substantially reduce the incidence of the disease. So suggest the results of a modelling study by Cancer Research UK and Julietta Patnick, director of the NHS cancer screening programmes. The research published in the British Journal of Cancer (August 2004) shows an 18% fall in cumulative lifetime incidence, compared with pre-2003 policy, and a reduction in the predicted lifetime incidence of invasive cervical cancer, from 0.77% (under pre-2003 policy) to 0.63%, compared with a 1.70% predicted incidence without screening. The research also found that continuing to screen the 20-25 age group would have had minimal impact. A five-year screening interval was retained for women aged 50-64 years.

You may also be interested in...



Basilea Stresses Derazantinib's FGFR Kinase Differentiation

Switzerland’s SIX exchange-listed drug development company, Basilea, is moving two new oncology candidates along its R&D pipeline, supported by strong revenues from two partnered anti-infective products.

 

ATMPs Put EU Cross-Border Healthcare On The Map

Recommendations from the Alliance for Regenerative Medicine aim to improve cross-border healthcare to ensure patients can access advanced therapies.

Start-Up Snapshot: Nanomedic’s Electro-Spinning, Portable Wound Care Device

At the OurCrowd Global Investor Summit in Jerusalem, Israel, on 13 February, Medtech Insight met wound care device company Nanomedic to find out more about its unique electro-spinning technology.

Topics

UsernamePublicRestriction

Register

MT059331

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel